Asitbiotech.com

Belgian clinical-stage biopharmaceutical firm ASIT Biotech has reported positive results from its Phase III clinical trial of gp-ASIT+ for the treatment of patients with grass pollen-induced allergic rhinitis.

DUBLIN, July 15, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Allergy Immunotherapies Market 2016-2020" report to their offering. The report foreCASts the global allergy immunotherapies market to grow at a CAGR...

Global Allergy Immunotherapies Industry 2017 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2017-2020. The analysts of the global Allergy Immunotherapies...

Stay connected to the top weekly SEC transactions with the SECurities Digest Newsletter from Business Law Center on WestlawNext. With Business Law Center, you\’ll get the deal and SEC filing highlights you need delivered right to your inbox. See below...

(Source: Euronext NV) Biopharmaceutical company specialized in allergies valued at € 89.3 million Brussels, Paris - 11 May 2016 - Euronext today celebrated the listing of ASIT biotech on its Brussels and Paris markets. ASIT biotech joins a community...